GENinCode H1 2025: 15% revenue growth, firm margins, FDA progress
GENinCode has posted a tidy step-up in first-half trading, with revenue up 15% to £1.6m and gross margin holding steady at 53%. Losses were unchanged at £2.4m, and period-end cash sat at £2.4m. Management says full-year trading is broadly in line with expectations and flags a busy second half.
There are two strategic threads to watch: the US FDA De Novo process and potential test distribution partnerships in the US and EU. Add fresh clinical data presented by Kaiser Permanente and at the European Society of Cardiology, and the narrative remains very much about building the evidence base and unlocking commercial channels.
Key numbers at a glance
| Metric | H1 2025 | H1 2024 |
|---|---|---|
| Revenue | £1.6m | £1.4m |
| Gross profit margin | 53% | 53% |
| Losses | £2.4m | £2.4m |
| Cash at period end | £2.4m | £2.9m |
Top-line growth with disciplined gross margin
Revenue growth of 15% to £1.6m is solid for a company still in the scaling phase, driven by activity across the UK, EU and US businesses. The 53% gross margin is unchanged year-on-year, which suggests pricing and cost of goods stayed well-controlled despite growth.
Losses of £2.4m match the prior year period. That tells us investment levels are broadly consistent, and the business is not yet at the point where operating leverage (more revenue dropping through to profit) is meaningfully improving the P&L. Cash of £2.4m is lower than the £2.9m reported at 30 June 2024. The company has not disclosed cash runway or guidance on funding in this update.
FDA De Novo: closing out the “short list of remaining deficiencies”
The De Novo pathway is the US route for novel diagnostic devices that don’t have a predicate (an approved direct comparator). Achieving De Novo classification can unlock national US marketing and tends to be a meaningful commercial catalyst.
GENinCode says discussions “continue to progress” with work ongoing to close the short list of remaining deficiencies. In FDA-speak, that means the company has received feedback from the regulator and is addressing outstanding points. No timeline is disclosed, but the language indicates they are in the later innings of review rather than at the starting line. Any resolution here would be material for the US launch strategy.
Distribution talks with a major partner: potential acceleration lever
The company notes ongoing “collaboration discussions on potential US and EU test distribution” with a major distributor. No name or terms are disclosed. If secured, a distribution agreement could accelerate market penetration without GENinCode having to build full-scale sales infrastructure in every geography.
For investors, the watch-out is disclosure: the market will likely want clarity on exclusivity, pricing, sales targets and geographies. Until then, treat this as a promising but unbanked catalyst.
Clinical momentum: Kaiser Permanente and ESC presentations
New data on CARDIO inCode-Score, the company’s polygenic risk score (a test that combines many genetic markers to estimate risk), was presented by Kaiser Permanente at the American Society of Preventive Cardiology in Boston, with a further presentation at the European Society of Cardiology Congress in Madrid.
The focus, per the RNS, is the clinical importance of CARDIO inCode-Score in the modulation of cholesterol risk for coronary heart disease. While detailed results are not disclosed here, high-profile presentations matter: they help build clinician awareness, support payer discussions, and strengthen the case for guidelines inclusion over time.
Why this update matters for the investment case
- Execution: 15% revenue growth with stable 53% gross margin shows the core commercial engine is functioning across regions.
- Regulatory catalyst: Progress on the FDA De Novo pathway is one of the biggest potential value inflection points for US revenue.
- Go-to-market leverage: A distribution deal with a major partner in the US and EU could compress the time to scale.
- Evidence base: Ongoing clinical presentations add weight to adoption arguments for CARDIO inCode-Score.
Balanced take: positives and pressure points
What looks positive
- Consistent top-line growth across the UK, EU and US despite a challenging diagnostics market.
- Gross margin resilience at 53% suggests sound unit economics.
- Regulatory and business development workstreams both advancing, offering multiple shots on goal for H2.
What to watch carefully
- Losses remain at £2.4m for the half, highlighting the need for scale before profitability comes into view.
- Cash of £2.4m at period end is lower than last year’s £2.9m. The company has not disclosed cash runway or funding plans in this update.
- Distribution and FDA milestones are not yet time-stamped. Without dates, investor patience can be tested.
Outlook: “broadly in line” and a busy H2
Management guides that trading is broadly in line with the Board’s expectations for the full year, with a busy second half anticipated. The next formal checkpoint is the 2025 Interim Report, expected at the end of September (exact date to be confirmed).
Near-term, the share price is likely to respond most to tangible progress on FDA De Novo, any announced distributor agreement, and further clinical or reimbursement developments. Operationally, maintaining double-digit revenue growth while protecting margin would underpin confidence.
Jargon buster
- Gross margin: the percentage of revenue left after the direct costs of producing the tests.
- De Novo (FDA): a US pathway for first-of-a-kind medical devices and diagnostics to gain market authorisation.
- Polygenic risk score: a genetic test that aggregates many small genetic signals to estimate a person’s disease risk.
My verdict
This is a steady, businesslike update. Revenue growth is encouraging, margins are holding, and the strategic levers – FDA approval, distribution partnerships, and strengthening clinical data – are moving in the right direction. The flip side is unchanged losses and a modest cash balance, with no new colour on runway.
If GENinCode can land either the FDA De Novo clearance or a credible distribution deal in H2, the commercial story could shift up a gear. Until then, it is a case of measured progress, with September’s interim report the next chance for deeper detail.
